Farnaz Amoozegar1, Scott B Patten2, Werner J Becker3, Andrew G M Bulloch2, Kirsten M Fiest3, W Jeptha Davenport4, Christopher R Carroll5, Nathalie Jette6. 1. Dept of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Canada. Electronic address: farnaz.amoozegar@albertahealthservices.ca. 2. Hotchkiss Brain Institute, Canada; Dept of Psychiatry, University of Calgary, Calgary, Alberta, Canada; Dept of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Mathison Centre for Mental Health Research & Education, Canada. 3. Dept of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Canada. 4. Dept of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Canada; Dept of Medical Genetics, University of Calgary, Calgary, Alberta, Canada. 5. Dept of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 6. Dept of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Canada; Dept of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; O'Brien Institute for Public Health, Canada.
Abstract
OBJECTIVES: Migraine and depression are common comorbid conditions. The purpose of this study was to assess how well the Patient Health Questionnaire (PHQ-9) and the Hospital Anxiety and Depression Scale (HADS) perform as depression screening tools in patients with migraine. METHODS: Three hundred consecutive migraine patients were recruited from a large headache center. The PHQ-9 and HADS were self-administered and validated against the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV, a gold standard for the diagnosis of depression. Sensitivity, specificity, positive predictive value, negative predictive value and receiver-operator characteristic curves were calculated for the PHQ-9 and HADS. RESULTS: At the traditional cut-point of 10, the PHQ-9 demonstrated 82.0% sensitivity and 79.9% specificity. At a cut-point of 8, the HADS demonstrated 86.5% sensitivity and specificity. The PHQ-9 algorithm performed poorly (53.8% sensitivity, 94.9% specificity). The point prevalence of depression in this study was 25.0% (95% CI 19.0-31.0), and 17.0% of patients had untreated depression. CONCLUSIONS: In this study, the PHQ-9 and HADS performed well in migraine patients attending a headache clinic, but optimal cut-points to screen for depression vary depending on the goals of the assessment. Also, migraine patients attending a headache clinic have a high prevalence of depression and many are inadequately treated. Future studies are needed to confirm these findings and to evaluate the impact of depression screening.
OBJECTIVES:Migraine and depression are common comorbid conditions. The purpose of this study was to assess how well the Patient Health Questionnaire (PHQ-9) and the Hospital Anxiety and Depression Scale (HADS) perform as depression screening tools in patients with migraine. METHODS: Three hundred consecutive migrainepatients were recruited from a large headache center. The PHQ-9 and HADS were self-administered and validated against the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV, a gold standard for the diagnosis of depression. Sensitivity, specificity, positive predictive value, negative predictive value and receiver-operator characteristic curves were calculated for the PHQ-9 and HADS. RESULTS: At the traditional cut-point of 10, the PHQ-9 demonstrated 82.0% sensitivity and 79.9% specificity. At a cut-point of 8, the HADS demonstrated 86.5% sensitivity and specificity. The PHQ-9 algorithm performed poorly (53.8% sensitivity, 94.9% specificity). The point prevalence of depression in this study was 25.0% (95% CI 19.0-31.0), and 17.0% of patients had untreated depression. CONCLUSIONS: In this study, the PHQ-9 and HADS performed well in migrainepatients attending a headache clinic, but optimal cut-points to screen for depression vary depending on the goals of the assessment. Also, migrainepatients attending a headache clinic have a high prevalence of depression and many are inadequately treated. Future studies are needed to confirm these findings and to evaluate the impact of depression screening.
Authors: Chen He; Brooke Levis; Kira E Riehm; Nazanin Saadat; Alexander W Levis; Marleine Azar; Danielle B Rice; Ankur Krishnan; Yin Wu; Ying Sun; Mahrukh Imran; Jill Boruff; Pim Cuijpers; Simon Gilbody; John P A Ioannidis; Lorie A Kloda; Dean McMillan; Scott B Patten; Ian Shrier; Roy C Ziegelstein; Dickens H Akena; Bruce Arroll; Liat Ayalon; Hamid R Baradaran; Murray Baron; Anna Beraldi; Charles H Bombardier; Peter Butterworth; Gregory Carter; Marcos Hortes Nisihara Chagas; Juliana C N Chan; Rushina Cholera; Kerrie Clover; Yeates Conwell; Janneke M de Man-van Ginkel; Jesse R Fann; Felix H Fischer; Daniel Fung; Bizu Gelaye; Felicity Goodyear-Smith; Catherine G Greeno; Brian J Hall; Patricia A Harrison; Martin Härter; Ulrich Hegerl; Leanne Hides; Stevan E Hobfoll; Marie Hudson; Thomas N Hyphantis; Masatoshi Inagaki; Khalida Ismail; Nathalie Jetté; Mohammad E Khamseh; Kim M Kiely; Yunxin Kwan; Femke Lamers; Shen-Ing Liu; Manote Lotrakul; Sonia R Loureiro; Bernd Löwe; Laura Marsh; Anthony McGuire; Sherina Mohd-Sidik; Tiago N Munhoz; Kumiko Muramatsu; Flávia L Osório; Vikram Patel; Brian W Pence; Philippe Persoons; Angelo Picardi; Katrin Reuter; Alasdair G Rooney; Iná S da Silva Dos Santos; Juwita Shaaban; Abbey Sidebottom; Adam Simning; Lesley Stafford; Sharon Sung; Pei Lin Lynnette Tan; Alyna Turner; Henk C P M van Weert; Jennifer White; Mary A Whooley; Kirsty Winkley; Mitsuhiko Yamada; Brett D Thombs; Andrea Benedetti Journal: Psychother Psychosom Date: 2019-10-08 Impact factor: 25.617
Authors: Dipika Neupane; Brooke Levis; Parash M Bhandari; Brett D Thombs; Andrea Benedetti Journal: Int J Methods Psychiatr Res Date: 2021-05-12 Impact factor: 4.182